Demographic and laboratory data of the studied patients with β-TM
| Variable | β-TM (n=50) |
|---|---|
| Age (years), mean±SD | 15.25±4.1 |
| Sex, n (%) | |
| Male | 24 (48) |
| Female | 26 (52) |
| Weight (kg), mean±SD | 40.6±9.2 |
| Height (cm), mean±SD | 146.3±103 |
| BMI (kg/m2), mean±SD | 18.8±2.6 |
| Disease duration (years), mean±SD | 14.5±2.6 |
| Positive family history, n (%) | 40 (80) |
| Transfusion index (mL/kg/year) | 126±45(59–222) |
| Splenectomised, n (%) | |
| Yes | 34 (68) |
| No | 16 (32) |
| Chelation therapy, n (%) | |
| Combined therapy | 27 (54) |
| Mono therapy | 23 (46) |
| Compliance to chelation, n (%) | |
| Good | 28 (56) |
| Poor | 22 (44) |
| Cardiac complications, n (%) | |
| Yes | 24 (48) |
| No | 26 (52) |
| Oral glucose tolerance test, n (%) | |
| Normal | 20 (40) |
| Impaired fasting glucose | 20 (40) |
| Overt diabetes | 10 (20) |
| Triglyceride (mg/dL), median (IQR) | 154 (134–211) |
| Triglyceride index, median (IQR) | 8.13 (6.6–10.62) |
| FBG (mg/dL), median (IQR) | 106 (100–143) |
| 2 h BG (mg/dL), median (IQR) | 130 (121–195) |
| ALT (U/L), median (IQR) | 44 (34–66) |
| Albumin (mg/dL), median (IQR) | 3.9 (3.5–4.1) |
| Ferritin (µg/L), median (IQR) | 2750 (1319–5516) |
| Amylase (IU/L), median (IQR) | 63.5 (44–84) |
| Lipase (IU/L), median (IQR) | 63 (42–83) |
| Cardiac T2* (ms), median (IQR) | 22 (12–31) |
| Hepatic T2* (ms), median (IQR) | 5.5 (4–9) |
ALT, alanine aminotransferase; β-TM, β-thalassaemia major; FBG, fasting blood glucose.